Physician profile
David Kay
NPI 1891796082
$6,731.24
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,919 · 2020: $3,607 · 2021: $58.06 · 2022: $108 · 2023: $15.83 · 2024: $23.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $3,750.00 | 2019-2020 | |
| Penumbra, INC. | $1,856.01 | 2019 | |
| Terumo Medical Corporation | $373.74 | 2019 | |
| Stryker Corporation | $166.46 | 2020 | |
| Biocompatibles, INC. | $140.39 | 2019 | |
| Argon Medical Devices, INC. | $108.98 | 2019 | |
| Allergan, INC. | $89.61 | 2022 | |
| Boston Scientific Corporation | $68.90 | 2019-2020 | |
| Inari Medical, INC. | $46.62 | 2019-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Sight Sciences, INC. | $40.68 | 2021 | |
| Sirtex Medical INC | $32.74 | 2019-2020 | |
| Glaukos Corporation | $23.66 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $17.38 | 2021 | |
| Shire North American Group INC | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.